Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) was the target of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 5,530,000 shares, an increase of 5.1% from the September 30th total of 5,260,000 shares. Approximately 4.0% of the shares of the stock are sold short. Based on an average trading volume of 520,300 shares, the short-interest ratio is presently 10.6 days.
A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in Matinas BioPharma by 39.7% in the 2nd quarter. Vanguard Group Inc. now owns 4,997,918 shares of the company’s stock worth $4,282,000 after buying an additional 1,419,118 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Matinas BioPharma by 5.0% in the 2nd quarter. BlackRock Inc. now owns 633,985 shares of the company’s stock valued at $543,000 after purchasing an additional 30,402 shares in the last quarter. Northern Trust Corp lifted its stake in shares of Matinas BioPharma by 30.1% in the 2nd quarter. Northern Trust Corp now owns 236,818 shares of the company’s stock valued at $203,000 after purchasing an additional 54,852 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Matinas BioPharma by 175.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 154,558 shares of the company’s stock valued at $132,000 after purchasing an additional 98,501 shares in the last quarter. Finally, Staley Capital Advisers Inc. acquired a new position in shares of Matinas BioPharma in the 2nd quarter valued at about $171,000.
A number of analysts recently commented on MTNB shares. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of Matinas BioPharma in a research note on Wednesday, August 14th. Maxim Group reaffirmed a “buy” rating and set a $3.00 price objective on shares of Matinas BioPharma in a research note on Thursday, September 26th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Matinas BioPharma currently has a consensus rating of “Buy” and a consensus price target of $3.60.
Matinas BioPharma (NYSEAMERICAN:MTNB) last issued its quarterly earnings results on Wednesday, November 13th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.03).
Matinas BioPharma Company Profile
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.
Featured Story: What is the role of the G-20?
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.